NCT05800223招募中3 期
Prospective, Multicenter, Randomized Controlled, Phase III Clinical Study of Armatinib Alone or in Combination With Stereotactic Body Radiotherapy (SRT) for First-line Treatment of Brain Metastases From EGFR-mutated Non-small Cell Lung Cancer
Shanghai Cancer Hospital, China1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2023年1月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- iPFS
研究概览
简要总结
Objective:Patients with asymptomatic or minimally symptomatic Stage IV EGFR-positive NSCLC with baseline intracranial metastases.
Aim: To investigate the timing, efficacy and safety of radiotherapy in patients with EGFR positive brain metastases treated with armatinib alone or combined with stereotactic radiotherapy.
Method: Almonertinib: specification 55mg/tablet; The dosage is 110 mg / day (2 tablets / day) orally once a day; SBRT: 3-5 doses of 27-40 Gy
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •aged 18 years or older (including 18 years) and up to 75 years (including 75 years)
- •histologically confirmed NSCLC (by AJCC 8th edition lung cancer staging criteria)
- •asymptomatic or minimally symptomatic brain metastases (i.e., headache, nausea, or seizures responding to dexamethasone/analgesic/antiepileptic agents at a stable drug dose for at least 3 days);
- •brain metastases must meet the following criteria on diagnostic MRI: at least one lesion that can be classified as measurable disease according to RANO-BM, ≤ 10 brain or brainstem metastases
- •epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation (alone or in combination with other EGFR mutations);
- •no prior systemic therapy other than neoadjuvant therapy, adjuvant therapy, or concurrent chemotherapy for more than 3 months prior to study entry
- •Eastern Cooperative Oncology Organization Group (ECOG) physical status score of 0 or 1 and no worsening in the previous 2 weeks, with a minimum expected survival of 12 weeks.
- •good hematopoietic function, defined as absolute neutrophil count ≥ 1.5 × 109 /L, platelet count ≥ 100 × 109 /L, and hemoglobin ≥ 90 g/L [no transfusion or erythropoietin (EPO-dependent) within 7 days
- •good coagulation, defined as an international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times ULN; if the subject is on anticoagulation therapy, as long as the PT is within the proposed range of anticoagulant medication
- •good liver function, defined as a total bilirubin level ≤ 1.5 times the upper limit of normal (ULN); glutathione transaminase (AST) and glutamate transaminase (ALT) levels ≤ 2.5 times the ULN for patients without liver metastases; and AST and ALT levels ≤ 5 times the ULN for patients with documented liver metastases
- •good renal function, defined as serum creatinine ≤ 1.5 times ULN or calculated creatinine clearance ≥ 60 ml/min; urine protein less than 2+ on routine urine examination, or 24-hour urine protein quantification < 1 g
- •Women of childbearing potential should have a negative urine or serum pregnancy test within 3 days prior to receiving the first dose of study drug (Week 1, Day 1).
- •male patients should be using barrier contraception (i.e., condoms) from screening until 6 months after discontinuation of study treatment
- •Subjects will voluntarily participate and sign an informed consent in writing.
排除标准
- •Received any of the following treatments:
- •Currently participating in an interventional clinical study treatment or received another study drug within 4 weeks prior to the first dose
- •Received palliative intracranial radiation therapy prior to the first dose
- •Patient has undergone major surgery (including biopsy) or major trauma within 4 weeks prior to the first dose of study drug; patients who are expected to require major surgery during the study period
- •Patients previously treated with EGFR-TKI.
- •patients with NSCLC EGFR driver gene negative or known severe allergic reactions (≥ grade 3) to TKIs drugs;
- •patients who are unable to undergo MR examination
- •brain metastases requiring surgical decompression;
- •the presence of a previous solid organ or hematologic transplant; clinically active diverticulitis, abdominal abscess, gastrointestinal obstruction; the presence of clinically uncontrollable pleural effusion/peritoneal effusion
- •malignancy other than non-small cell lung cancer within 5 years prior to enrollment, excluding adequately treated carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer of the skin, localized prostate cancer after radical surgery, and ductal carcinoma in situ of the breast;
- •having unremitting residual toxicity of prior therapy greater than CTCAE grade 1 at the time of initiation of study treatment, with the exception of alopecia and grade 2 neurotoxicity from prior chemotherapy;
- •have any serious or poorly controlled systemic disease, such as active bleeding-prone body or active infection, as judged by the investigator. Chronic illnesses that do not require exclusion;
- •the known presence of a psychiatric illness or substance abuse condition that may have an impact on compliance with trial requirements
- •any serious or uncontrolled ocular pathology that, in the judgment of the physician, may increase the safety risk to the patient
- •a known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive)
- •patients who, in the judgment of the investigator, are likely to be poorly compliant with the procedures and requirements of the study.
研究组 & 干预措施
GroupA
Experimental
Intracranial stereotactic radiotherapy (27-40 Gy/3-5f) was administered to all intracranial lesions on the first day of oral administration of Almonertinib
干预措施: Almonertinib (Drug)
GroupC
Experimental
oral administration of Almonertinib
干预措施: Almonertinib (Drug)
GroupA
Experimental
Intracranial stereotactic radiotherapy (27-40 Gy/3-5f) was administered to all intracranial lesions on the first day of oral administration of Almonertinib
干预措施: SBRT (Radiation)
GroupB
Experimental
Two successive MR enhancements after oral administration of Almonertinib suggest that intracranial lesions are maximally remission, and stereotactic body radiotherapy is given to all lesions (27-40Gy/3-5f)
干预措施: Almonertinib (Drug)
GroupB
Experimental
Two successive MR enhancements after oral administration of Almonertinib suggest that intracranial lesions are maximally remission, and stereotactic body radiotherapy is given to all lesions (27-40Gy/3-5f)
干预措施: SBRT (Radiation)
结局指标
主要结局
iPFS
时间窗: up to 12 months
Intracranial to time to disease progression
次要结局
未报告次要终点
研究者
Fan Min
Clinical Professor
Shanghai Cancer Hospital, China
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung CancerNCT02157883AstraZeneca39
招募中
不适用
A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain MetastasesEGFR Gene MutationEGF-R Positive Non-Small Cell Lung CancerBrain MetastasesNon-small Cell Lung CancerNSCLCNCT05033691Hadassah Medical Organization162
进行中（未招募）
1 期
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Metastatic Non Small Cell Lung CancerNCT04743505Washington University School of Medicine27
终止
2 期
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).Non-Squamous Non-Small Cell Lung CancerNCT00760929Hoffmann-La Roche171
Unknown
2 期
Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line TherapyNSCLCNCT01579630Taipei Veterans General Hospital, Taiwan52